Your session is about to expire
← Back to Search
ACT001 for Brain Tumor
Study Summary
This trial is testing a new cancer treatment that could be more effective than current treatments.
- Brain Tumor
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to ACT001 or similar substances.You have a history of lung inflammation that is not caused by an infection and is currently active.You are using an intrauterine device (IUD) that has a very low chance of not working (less than 1% per year).You have received previous treatment with immune checkpoint blockade (CPB) or drugs like Avastin that target blood vessels.It is possible for you to undergo another surgery if needed.The doctor believes that the patient is not suitable for the study for any other reason.You have taken a medication called everolimus, which suppresses your immune system, within the past four weeks.You must use two forms of birth control, like a condom and a diaphragm, to prevent pregnancy.You do not have worsening neurological symptoms, new seizures, or the need for higher doses of corticosteroids.You should not have any major side effects from previous treatments that have not improved to a mild level (Grade 1) unless stated otherwise.You are able to take care of most of your needs with occasional help.
- Group 1: 1b dose exploration
- Group 2: 2a- Randomized/Two-treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial currently enrolling new participants?
"According to clinicaltrials.gov, this medical investigation is currently seeking out suitable participants. The trial was published on September 22nd 2021 and the most recent amendment occurred November 12th of the same year."
What medical application is ACT001 most frequently employed for?
"ACT001 is traditionally used to treat malignant neoplasms, and has also been found effective in managing conditions such as unresectable melanoma, microsatellite instability high, or disease progression caused by chemotherapy."
To what degree has ACT001 been explored in other research efforts?
"Presently, 961 clinical trials are underway to investigate ACT001 with 122 of them in the advanced Phase 3 stage. Houston is the epicentre for these studies but there are an additional 35,731 sites actively running tests related to this medication."
What is the ceiling for participants in this clinical trial?
"Affirmative. The clinical trial is actively recruiting, as stated on the official website of clinicaltrials.gov which records that it was first posted in September 2021 and recently updated in November 2021. 48 participants are required across 1 site of enrollment."
Share this study with friends
Copy Link
Messenger